Cell and Gene Therapy Market Size, Share & Industry Analysis, By Type (By Cell Therapy {By Therapy Type [CAR-T Cell Therapy, TCR-T Cell Therapy, Natural Killer Cells, &Others], By Product (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, & Others], By Indication [Oncology & Others]}, and By Gene Therapy {By Vector Type [Viral Vectors & Non-Viral Vectors], By Product Type [Zolgensma, Luxturna, Roctavian, & Others], and By Indication [Genetic Diseases, Ophthalmology, Hematology, & Others]}), By End User (Hospitals & Clinics, Specialty Clinics, & Others), and Regional Forecast, 2026-2034

Last Updated: April 27, 2026 | Format: PDF | Report ID: FBI114130

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 31.10% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Type, End User, and Region
By Type	Cell Therapy By Therapy Type CAR-T Cell Therapy TCR-T Cell Therapy Natural Killer (NK) Cells Others By Product Kymriah Yescarta Tecartus Breyanzi Abecma Carvykti Others By Indication Oncology Others Gene Therapy By Vector Type Viral Vectors Non-Viral Vectors By Product Type Zolgensma Luxturna Roctavian Others By Indication Genetic Diseases Ophthalmology Hematology Others
By End User	Hospitals & Clinics Specialty Clinics Others
By Region	North America (By Type, End User, and Country) U.S. Canada Europe (By Type, End User, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Type, End User, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Type, End User, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Type, End User, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa